Death
|
17
|
-0.02
|
-0.05
|
0.01
|
74.8
| |
NNTH 62.4 to ∞ to NNTB 23.4
|
0
|
M-H
|
low
|
High quality studies
|
6
|
-0.02
|
-0.06
|
0.02
| |
624.6
|
NNTH 24.6 to ∞ to NNTB 26.7
|
34.1
|
M-H
|
Aprotinin
|
11
|
-0.01
|
-0.05
|
0.02
|
89.3
| |
NNTH 38.8 to ∞ to NNTB 20.8
|
0
|
M-H
|
Gabexate mesilate
|
6
|
-0.02
|
-0.07
|
0.03
|
54.3
| |
NNTH 33.3 to ∞ to NNTB 14.9
|
31.1
|
M-H
|
Daily dosage >900 mg of GM
|
5
|
-0.02
|
-0.09
|
0.04
|
55.2
| |
NNTH 8.3 to ∞ to NNTB 14.C
|
47.0
|
M-H
|
Daily dosage >1500 mg of GM
|
2
|
-0.09
|
-0.33
|
0.15
|
33.6
| |
NNTH 17.8 to ∞ to NNTB 8.6
|
79.0
|
D-L
|
Mild pancreatitis
|
7
|
0.00
|
-0.03
|
0.04
| |
177.5
|
NNTH 24.5 to ∞ to NNTB 33.9
|
0
|
M-H
|
Moderate to severe pancreatitis
|
10
|
-0.03
|
-0.07
|
0.01
| |
1604
|
NNTH 23.0 to ∞ to NNTB 23.7
|
19.7
|
M-H
|
Severe pancreatitis
|
2
|
-0.19
|
-031
|
-0.08
|
5.2
| |
3.2 to 12.7
|
0
|
M-H
|
With sponsor
|
9
|
-0.02
|
-0.06
|
0.02
|
67.0
| |
NNTH 43.0 to ∞ to NNTB 18.8
|
15.0
|
M-H
|
Without sponsor
|
8
|
-0.02
|
-0.06
|
0.03
|
68.4
| |
NNTH 31.9 to ∞ to NNTB 16.5
|
0
|
M-H
|
Abdominal pain
|
2
|
-0.26
|
-0.40
|
-0.13
|
3.9
|
2.5 to 9.6
|
85.0
|
D-L
| |
very low
|
High quality study
|
1
|
-0.14
|
-0.32
|
0.03
|
6.9
| |
NNTH 30.1 to ∞ to NNTB 3.1
|
Uncalculatable
|
M-H
|
Pseudocyst formation
|
5
|
-0.00
|
-0.05
|
0.03
|
298.6
| |
NNTH 27.3 to ∞ to NNTB 23.1
|
0
|
M-H
|
low
|
Intra-abdominal abscess formation
|
4
|
-0.01
|
-0.04
|
0.02
|
113.2
| |
NNTH 65.3 to ∞ to NNTB 30.3
|
0
|
M-H
|
low
|
Surgical intervention
|
3
|
-0.08
|
-0.17
|
-0.00
|
11.8
| |
6.0 to 443.8
|
60.5
|
D0L
|
very low
|
High quality study
|
1
|
0.00
|
-0.10
|
0.11
| |
225.8
|
NNTH 8.9 to ∞ to NNTB 9.7
|
Uncalculatable
|
M-H
|
Bowel obstruction
|
3
|
-0.06
|
-0.12
|
-0.00
|
6.3
| |
4.0 to 14.5
|
58.8
|
D-L
|
very low
|
High quality study
|
1
|
-0.03
|
-0.08
|
0.02
|
33.9
| |
NNTH 44.2 to ∞ to NNTB 12.3
|
Uncalculatable
|
M-H
|
Any major complications
|
5
|
-0.01
|
-0.08
|
0.06
|
76.4
| |
NNTH 15.7 to ∞ to NNTB 11.1
|
0
|
M-H
|
low
|